Study of the Effectiveness and Safety of Niaspan ® in the Treatment of Lipid Abnormalities in Latin America
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
Post-Marketing Observational study of Niaspan® tablet in accordance with each country
regulations. This study will be conducted in a prospective, single-arm, multi-center format.
As this study is observational in nature, the follow-up of subject's is not prescriptive in
nature and is according to the judgment of the physician (investigator in the course of
treatment for each patient), within the period of observation of 12 months. This includes an
enrollment period of 6 months in which each subject will be observed for approximately 6
months. Examinations, diagnostic measures, findings and observations performed as per usual
medical practice during the observation period will be recorded on Case Report Forms (CRFs)
by the investigator or site staffs according to the protocol.